Latest News and Press Releases
Want to stay updated on the latest news?
-
NORTHVALE, N.J., Oct. 19, 2011 (GLOBE NEWSWIRE) -- Elite Pharmaceutical, Inc.'s ("Elite" or the "Company") (OTCBB:ELTP) today announced that all resolutions proposed at the Company's October 18th...
-
NORTHVALE, N.J., Sept. 27, 2011 (GLOBE NEWSWIRE) -- Elite Pharmaceutical, Inc.'s ("Elite" or the "Company") (OTCBB:ELTP) and ECR Pharmaceuticals ("ECR"), a wholly owned subsidiary of Hi-Tech Pharmacal...
-
NORTHVALE, N.J., Aug. 16, 2011 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. (OTCBB:ELTP),a specialty pharmaceutical company dedicated to developing and commercializing oral controlled release...
-
NORTHVALE, N.J., Aug. 11, 2011 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. (OTCBB:ELTP), a specialty pharmaceutical company dedicated to developing and commercializing oral sustained and...
-
NORTHVALE, N.J., June 30, 2011 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. (OTCBB:ELTP), a specialty pharmaceutical company dedicated to developing and commercializing oral controlled release...
-
NORTHVALE, N.J., June 29, 2011 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite") (OTCBB:ELTP) today announced that it has entered into a commercial Manufacturing and Supply Agreement with...
-
NORTHVALE, N.J., June 24, 2011 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. (OTCBB:ELTP), a specialty pharmaceutical company dedicated to developing and commercializing oral sustained and...
-
NORTHVALE, N.J., June 6, 2011 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite") (OTCBB:ELTP) today announced that it has entered into a commercial Manufacturing and Supply Agreement with Mikah...
-
NORTHVALE, N.J., June 6, 2011 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite") (OTCBB:ELTP) today announced that on May 31, 2011, it had been notified by the US Food and Drug Administration...
-
NORTHVALE, N.J., May 24, 2011 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite") (OTCBB:ELTP) today announced that all of the outstanding shares of its Series D 8% Convertible Preferred Stock...